After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Alnylam Pharmaceuticals Inc (ALNY) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.01%, to $161.52. The Alnylam Pharmaceuticals Inc has recorded 36,006 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity.
ALNY belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $161.53 and fluctuated between $163.27 as its day high and $148.73 as its day low. The current market capitalization of Alnylam Pharmaceuticals Inc is $20.19B. A total of 0.79 million shares were traded on the day, compared to an average of 634.32K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, ALNY has seen 8 BUY and 34 SELL insider trades, representing the acquisition of 33,136 and the disposition of 25,649 shares. Over the last 12 months, there were 29 BUYs and 87 SELLs from insiders. Insiders purchased 163,097 shares during that period but sold 132,543.
In the most recent transaction, Garg Pushkal sold 4,166 shares of ALNY for 183.89 per share on Aug 07. After the transaction, the CMO & EVP Dev & Med Affairs now owns 4,345 company shares. In a previous transaction on Aug 04, Vaishnaw Akshay sold 4,057 shares at 185.85 per share. ALNY shares that President owns now total 22,774.
Among the insiders who sold shares, Greenstreet Yvonne disposed of 4,057 shares on Aug 04 at a per-share price of $185.85. This resulted in the Chief Executive Officer holding 35,216 shares of ALNY after the transaction. In another insider transaction, Garg Pushkal sold 3,461 shares at $185.85 per share on Aug 04. Company shares held by the CMO & EVP Dev & Med Affairs now total 8,511.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ALNY in the last 3 months, the mean price target is $226.46 with high estimates of $395.00 and low estimates of $125.00. In terms of 52-week highs and lows, ALNY has a high of $242.97 and a low of $148.10.
As of this writing, ALNY has an earnings estimate of -$1.36 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $0.67 per share and a lower estimate of -$1.94. The company reported an EPS of -$1.4 in the last quarter, which was 20.50% higher than expectations of -$1.76.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALNY is Buy with a score of 4.32.